Introduction
============

Renal cell cancer (RCC) represents 2%\~3% of all cancers, and about 75% of RCC are clear cell renal cancer (ccRCC) [@B1]. The estimated new cases and deaths were 63,990 and 14,400 in the US in 2017, and the number of new cases and deaths of renal cancer respectively were 15.6 per 100,000 and 3.9 per 100,000 men and women per year [@B2]. In China, It was predicted that there would be about 66,800 newly diagnosed renal cancer cases and 23,400 deaths in 2015, namely 5.3 per 100,000 and 1.8 per 100,000 new cases and deaths [@B3]. Despite the incidence rates of RCC stabilized during these years, due to the relatively high incidence, RCC has become one of the most important healthcare issues worldwide.

Copy number alteration (CNA) is one of the important genetic variations, whose regions of variation range from 1kbp to 1mbp, and is widely distributed in the human genome. Besides, some functional genes included in CNA maybe play a key role in the tumorigenesis, prognosis and response to drug treatment [@B4]. For example, the copy number loss (CN loss) of tumor suppressor genes would affect the regulation of cell proliferation, leading to uncontrollable proliferation, and then cause cancer. In addition, the copy number gain (CN gain) of oncogenes also results in tumor occurrence, because of the accumulation of oncogenesis effect [@B5]. Although there are many studies on RCC CNA, few studies are based on the Chinese population. In this study, our objective is to acquire the whole genome CNA landscape in Chinese population and explore the tumor risk-associated functional genes in the CNA regions, by detecting the whole genome in the ccRCC tissues.

Materials and Methods
=====================

Patients and tissues
--------------------

All ccRCC specimens were from Huashan hospital, Fudan University. The inclusion criteria were: (1) Patients received radical nephrectomy or partial nephrectomy via open procedure or laparoscopic procedure because of kidney tumor; (2) the specimens were diagnosed with ccRCC by department of Pathology in our hospital (all the specimens were reviewed by the same group of pathologists.); (3) Clinical information was collected. Patients who were diagnosed with other types of kidney tumor, had missing clinical information were excluded. Finally, 35 FFPE (Formalin Fixed Paraffin Embedded) samples were included. The study was approved by the institutional review board of Huashan Hospital, Fudan University, Shanghai, China.

The whole genome in the ccRCC and Statistical Analysis
------------------------------------------------------

The whole-genome DNA was isolated and purified from FFPE samples using QIAamp DNA FFPE Tissue Kit (QIAGEN), and was quantified using the Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies). Then, the DNA was processed by use of Oncoscan (Affymetrix Inc) assay, and array fluorescence intensity data (CEL files), generated by Affymetrix® GeneChip® Command Console® (AGCC) Software version 4.0 were processed using OncoScan® Console software to produce OSCHP files and a set of QC metrics (inclusion criteria: MAPD ≤0.3 and ndSNPQC ≥26). And then, the OSCHP files were analyzed and displayed by the software Nexus Express for Oncoscan 3.0 [@B6]. Finally, the visible data and whole genome CNA landscape were acquired, and the CNA frequency was calculated by Nexus Express for Oncoscan 3.0. Besides, genes annotation and enrichment analyzing were processed by the method of BP (Biological Process), GO (Gene ontology) in the DAVID database (the Database for Annotation, Visualization and Integrated Discovery), and the significant threshold was set as *P*-value \<0.05. Then the functional genes related to biology process of oncogenesis in the CNA regions were further explored. Furthermore, the heatmap was conducted by R program (version 3.2.2). The SPSS (version 22) was used to analyze the gene burden and the affected base pair (bp) per million bp (Mbp) regions in the whole genome by comparison of different T stage affected by CNA.

Results
=======

Baseline characteristics of the patients
----------------------------------------

In the Oncoscan assay, a total of 35 ccRCC samples were finally included in this study, of which 21 (60%) were male and 14 (40%) were female. The mean age of the cases was 57.6±9.6 and the mean body mass index (BMI) was 24.46±3.1. According to the TNM stage, there were 22 patients (63%) with T1a stage (tumor size ≤4cm), 6 patients (17%) with T1b stage (4cm\< tumor size ≤7cm), 4 patients (11%) with T2a stage (7cm\< tumor size ≤10cm), 2 patients (6%) with T2b stage (tumor size \>10cm, but tumor confined to kidney), 1 patients (3%) with T3a stage (tumor grossly extends into the renal vein) (Table [1](#T1){ref-type="table"}).

Landscape of whole-genome CNA in Chinese population
---------------------------------------------------

The whole-genome CNA were detected in 35 ccRCC FFPE samples using Oncoscan assay. The software Nexus Express for Oncoscan 3.0 was used to analyze the raw data, generate the visible data, and depict the landscape of whole-genome CNA (Fig. [1](#F1){ref-type="fig"}A and Fig. [1](#F1){ref-type="fig"}B). In this CNA landscape, the red and blue areas respectively represented CN loss and CN gain, and the statue of whole-genome CNA in 24 chromosomes of 35 ccRCC samples was observed clearly. For example, we could notice the obvious CN loss in the whole chromosome 3p, partial chromosome 8p and chromosome 22q, and the frequencies of occurrence were high. Besides, we could notice the CN gain regions of high frequencies in chromosome 5q, chromosome Xq and Xp. Furthermore, the heatmap (Oncoprint) was depicted based on CNA regions of high frequency and representative functional genes (Fig. [2](#F2){ref-type="fig"}). This heatmap showed CN losses (blue) and gains (red) in 35 samples with Ocoscan assay data, and the affected genes in each locus that harbor CNA were listed in the parentheses. In this heatmap, the left histograms showed percentages of affected samples.

Based on the outcomes of Ocoscan assay in our study, we chose some CNA regions which had high frequency (≥20%) to make comparison with the Cancer Genome Atlas (TCGA) database on CNA associated with ccRCC (Table [2](#T2){ref-type="table"}). In the first four columns of Table [2](#T2){ref-type="table"}, we listed the high-frequency CNA regions we found from Ocoscan assay, among which the CN gain in 11p11 (MDK), 22q11.23 (PLA2G6), Xp22.33 (XGY3), and the CN loss in 20q11.3 (PDRG1), 16p11.2-p11.1 (SMG1P2), were found for the first time. Compared with TCGA database, the CNA frequency of some regions in Chinese was obviously higher, for example, 3p25.3 (VHL), 5q35.3 (SQSTM1), 13q21 (RB1), 17q21.33 (ABCC3), and Xq28 (SPRY3) so on. So the functional genes located in these CNA regions had a potential to become the RCC biomarkers. In the [Supplementary Table 1](#SM0){ref-type="supplementary-material"}, more CNA regions in Chinse were compared with TCGA cohort.

Genes functional annotation and enrichment
------------------------------------------

For the further study on the CNA regions and the genes located in these regions, 4437 genes which were located in the CNA regions (the frequency ≥10%) were included to conduct the analyzing of genes annotation and enrichment by the method of biological process in the Database for Annotation, Visualization and Integrated Discovery (DAVID). During this process, we set the significant threshold as *P*-value \<0.05, and acquired a few potential biological processes and functional genes related to the oncogenesis and tumor progression (Fig. [3](#F3){ref-type="fig"}). For example, the functional genes which were enriched in the Wnt signal pathway (PSME2, PSMB11, PSMB5) and Notch signal pathway (FOXA1, MMP14, MDK), DNA repair pathway (REC8, DDB2, FAN1, TTC5, etc.), DNA modification pathway (DNMT3A, ASCC1, CTCF, etc.). Furthermore, these functional genes in different pathways which were significantly enriched were compared with TCGA database (Table [3](#T3){ref-type="table"}). Finally, some higher-frequency functional genes and new-found genes were screened out, which might play a role in the oncogenesis and tumor progression, and be the tumor-related risk factors.

Oncogenes, Tumor suppressor genes and Fusion genes
--------------------------------------------------

Through much deeper analyzing 4437 genes which were located in the CNA regions (the frequency ≥10%), we explored and selected out 23 tumor suppressor genes located in CN loss regions (TADA3, VHL, PLCD1, CSRNP1, LZTFL1, LRRC2, NAT6, TUSC2, RASSF1, PCBP4, BAP1, ERC2-IT1, PTPRG, FOXP1, etc.), and 10 oncogenes (ABL2, RAB10, ADGRA3, BRAF, MET, LYN, MOS, RAB2A, RNF139, HUWE1) which were located in CN gain regions (Table [4](#T4){ref-type="table"}). There were still no studies on these functional genes associated with ccRCC, except for three genes (VHL, BAP1, MET). Besides, among these functional genes, the CNA of tumor suppressor gene (ERC2-IT1) and oncogenes (RAB10, ADGRA3) were not reported either in TCGA database. Interestingly, except for some higher-frequency genes and no-reporter genes, the opposite results of some CNA genes between Oncoscan assay and TCGA were also noticed, such as TSC2, RNF40 and HUWE1.

To explore the fusion genes, we chose a few high-frequency CN loss regions for further analyzing, such as 3p, 3q25.33-q26.1 and 22q11.23. Although we did not find the phenomenon of gene fusion in 3p and 3q25.33-q26.1, we observed the relatively high-frequency gene fusion in 22q11.23 (Fig. [4](#F4){ref-type="fig"}). When the CN loss of certain fragment in 22q11.23 occurred, two genes fusion (GSTTP1 and GSTTP2) which were located at two sides of CN loss fragment happened. And in 35 samples, gene fusion occurred in 16 samples (46%).

The comparison between different T stages affected by CNA
---------------------------------------------------------

In the Table [5](#T5){ref-type="table"}, the statistical difference among different T stages was calculated on some high-frequency CNA regions. Although there were no significance in the group of CN loss, CN gain, LOH (loss of heterozygosity), the significant difference of total CNA between T1 group and T2+T3 group was noticed (*P*-value =0.012), which mean T2+T3 group carried more high-frequency CNA regions ([Supplementary Table 2](#SM0){ref-type="supplementary-material"}). In the [Supplementary Table 3](#SM0){ref-type="supplementary-material"}, we calculated the number of genes affected by CNA in every T stage patient, namely gene burden, and compared the difference between T1 and T2+T3 stage. But there were no significance in the group of CN loss, CN gain, LOH, and total CNA (*P*-value \> 0.05). As the [Supplementary Table 4](#SM0){ref-type="supplementary-material"} showed, the affected bp per Mbp regions in the whole genome (about 3000Mbp) of every patient were analyzed, and the significance on different T stages in the group of CN loss, CN gain, LOH, and total CNA were not found out (*P*-value \> 0.05).

Discussion
==========

As far as we know, it is the first time that the whole-genome CNA in ccRCC was reported in the Chinese population, and the landscape of whole-genome CNA in ccRCC was acquired. In this study, we found out a few CNA regions which were not reported in previous studies, and discovered some new functional genes associated with ccRCC which had definite biological meaning. For example, the CN loss of tumor suppressor genes and DNA repair genes, the CN gain of oncogenes, fusion genes, etc. Commonly, gene dose effect, loss of gene function, and gene fusion were three likely mechanisms in CNA that would lead to the disease [@B7]. Therefore, these functional genes had potential to become the biomarkers of ccRCC, and were used for early diagnosis and guidance of follow-up.

In previous studies, researchers acquired the somatic CNAs by detecting 385 ccRCC samples with gene sequencing [@B8]. They discovered a few high-frequency CNA regions and functional genes, for example, the CN loss in 3p21.1, 14q24, 9p21.3 (CDKN2A), 6q26 (QKI), 8p11, 10q23 (PTEN), 1p26, 4q35, 13q21 (RB1), 15q21, 2q37, and the CN gain in 5q35, 8q24 (MYC), 3q26 (MECOM), 1q32 (MDM4). It was supposed that CN loss of tumor suppressor genes (CDKN2A, PTEN, RB1) and CN gain of oncogene (MYC) could be closely associated with tumorigenesis [@B8],[@B9]. In another study, it reported some high-frequency CNA regions and functional genes by whole-genome sequencing in 85 ccRCC samples, for example, EPM2AIP1 and SUSD5 at 3p22-p24, APEH, SETD2 and SMARCC at 13p21.31, SLC6A6 and VHL at 3p25, YLPM1 at 14q24.3, C14orf39 at 14q23, PNLIP at 10q25, DOCK2 at 5q35.1, KAT5 at 11q13.1, CHRNB2 and ECM1 at 1q21.2, AKAP9 and MUC17 at 7q11-q22 [@B10]. It was reported that ccRCC was characterized by loss of function of the tumor suppressor VHL and activation of hypoxia-inducible transcription factors (HIFs), and the VHL gene product (pVHL) targeted HIFs transcription factors for proteasomal degradation, and then increased HIF2a promotes pVHL-defective tumorigenesis [@B11]-[@B13]. There was a study that showed 5q amplification led to overexpression of the SQSTM1 oncogene in ccRCC lines and tumors, and the gene product of which, p62, regulated known renal cancer suppressor genes such as VHL, TSC1and TSC2 [@B14],[@B15]. Therefore, SQSTM1 was regarded as a pathogenic target of 5q CN gains in renal cancer. Besides, there were studies suggested that the CN loss of tumor suppressor CDKNA2 at 9p and the CN gain of oncogene MET at 7q31.1 were closely related to RCC, having the potential predictive value to guide targeted therapy [@B16],[@B17].

In the Table [3](#T3){ref-type="table"}, we listed the new-found functional genes that were not reported before in ccRCC, including DNA repair genes, DNA modification genes, Notch signal pathway genes, and Wnt signal pathway genes. The previous studies validated that the alterations in DNA repair genes were closely associated with tumorigenesis and prognosis, including renal cancer [@B18],[@B19]. In DNA modification genes we found, several studies showed that CN loss of CTCF at 16q22.1 and its low expression occurred in breast cancer and Wilms tumor of the kidney [@B20],[@B21]. A study demonstrated that CNA led to Notch pathway activation in ccRCC, and relevant gene products were also overexpressed and associated with gene amplification in distinct ccRCC samples [@B22]. The high-frequency CN gain of MDK at 11p11.2 in our study might validate these outcomes. Moreover, another study indicated that lower FOXA1 expression might be a marker of aggressive disease in upper tract urothelial carcinoma undergoing radical nephroureterectomy [@B23]. This outcome might be an evidence to prove that CN loss of FOXA1 at 14q11.2 was associated with ccRCC in our study. There was a research indicated that the low expression of the Wnt signal pathway gene (Wnt7A) was detected in the majority of ccRCC, and might have tumor suppressor properties [@B24]. Therefore, this result might be also a proof to verify that CN loss of PSME2, PSMB11, PSMB5 was associated with ccRCC in our study.

In the Table [4](#T4){ref-type="table"}, we made a list of functional genes, including 23 tumor suppressor genes located in CN loss regions and 10 oncogenes at CN gain regions. The previous studies had validated that CN loss of tumor suppressors VHL, BAP1, and CN gain of oncogene MET might play a role in tumorigenesis and progression [@B16],[@B25]. For the rest of genes listed in Table [4](#T4){ref-type="table"}, there were still no studies on ccRCC CNA in these functional genes. In short, all they had the potential to become markers of ccRCC. For the fusion genes, although both GSTTP1 and GSTTP2 were pseudogene, GSTTP1 still took part in Glutathione metabolism. As we know, the metabolic change was one of the important characters of tumor cells. Moreover, more and more researches revealed that pseudogene could regulate normal genes or express a part of protein, and the alteration in pseudogene might result in cancer [@B26]. Actually, we should further design the primers corresponding to GSTTP1 and GSTTP2, to validate the existing of gene fusion by PCR test.

In addition, the CNA frequency of some regions in Chinese was obviously higher when compared with TCGA database. Some genes which were found to be deleted in the TCGA database are amplified in our Ocoscan assay (e.g., EGFR, etc.), while some genes which were found to be amplified in the TCGA are deleted in our study (e.g., TSC2, etc.). However, it is hard to conclude whether the discrepancy is indeed due to race (Chinese population versus European Americans) or merely due to small study size. A future larger cohort should also be conducted to validate these findings.

Several limitations of the current study should be noted. (1) The sample size is relatively small in this study. It is hard to conclude whether the discrepancy is indeed due to race (Chinese population versus European Americans) or merely due to small size. It would be more persuasive to conduct Oncoscan assay on more samples. (2) The differences which had CNA regions or genes between different T stages were not detected, probably because of the small sample size which limited the statistic significance. (3) For the functional genes we found in this study, the validation by low-throughput method (MLPA, HRM-PCR, etc.) should be done in larger scale of samples. (4) The study on expression of functional genes is lacking, we will conduct the related experiment to validate the function of these genes in the next step.

Conclusion
==========

In this study, we acquired the whole-genome ccRCC CNA landscape in the Chinese population, discovered a few functional genes and fusion genes related to ccRCC in the CNA regions which maybe play a role in the biological process of tumor tumorigenesis. However, the larger scale of samples still is needed to validate our results.
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![Landscape of whole-genome copy number alteration (CNA). The red and blue areas respectively represented copy number loss and copy number gain, and the statue of whole-genome CNA in 24 chromosomes of 35 clear cell renal cancer samples was observed clearly.](jcav11p0016g001){#F1}

![Heatmap based on copy number alteration regions of high frequency and representative functional genes. The red and blue areas respectively represented copy number loss and copy number gain. The left histograms showed percentages of affected samples.](jcav11p0016g002){#F2}

![Genes functional annotation and enrichment. 4437 genes which were located in the CNA regions with the frequency ≥10% were included in the Database for Annotation, Visualization and Integrated Discovery to analyze genes annotation and enrichment.](jcav11p0016g003){#F3}

![The relatively high-frequency gene fusion in 22q11.23. The red and blue areas respectively represented copy number loss and copy number gain. Two genes fusion (GSTTP1 and GSTTP2) located at two sides of copy number loss fragment were observed.](jcav11p0016g004){#F4}

###### 

Demographic and clinical information of study population

  Variables                         ccRCC (n=35)   
  --------------------------------- -------------- -----------
  No. of cases                      35             
  Age (yr), Median (range)          55 (40-85)     
  **Gender (n, %)**                                
                                    Male           21 (60%)
                                    Female         14 (40%)
  Tumor size (cm), Median (Range)   3.5 (2-13)     
  **T Stage (n, %)**                               
                                    T1a            22 (63%)
                                    T1b            6 (17%)
                                    T2a            4 (11%)
                                    T2b            2 (6%)
                                    T3a            1 (3%)
  **N stage (n, %)**                               
                                    N0             35 (100%)
                                    N1             0
  **M stage (n, %)**                               
                                    M0             35 (100%)
                                    M1             0
  **Furhman (n, %)**                               
                                    I              1 (3%)
                                    II             17 (48%)
                                    III            3 (9%)
                                    IV             0
                                    Missing        14 (40%)

ccRCC, clear cell renal cancer; yr, year.

###### 

CNAs of ccRCC with highest frequencies (≥20%) in Chinese and the comparison with TCGA cohort (mainly European Americans)

  Chr   Region        Chinese (n=35)            TCGA (n=537)         Affected Genes      
  ----- ------------- ---------------- -------- -------------- ----- ---------------- -- -------------------
  3     p26.2         Del              48.57%                  Del   91%                 MECOM
        p25.3         Del              71.43%                  Del   11%                 VHL
        p22-p21       Del              74.29%                  Del   89-92%              BAP1, SETD2
        p12.1         Del              31.43%                  Del   51%                 CADM2
        q21           Amp              31.43%                  Amp   0.4%                CNBP
  5     q31.2         Amp              51.43%                  Amp   14%                 EGR1, PKD2L2
        q35.3         Amp              48.57%                  Amp   15%                 SQSTM1
  7     q22.1         Amp              20.00%                  Amp   0.7%                RADIL, TRRAP, ZAN
  8     q24.21        Amp              25.71%                  Amp   15%                 MYC
  11    p11           Amp              31.43%                  \-    \-                  OR4C12,MDK
  13    q21           Del              22.86%                  Del   0.20%               RB1
  14    q             Del              51.43%                  Del   45%                 HIF1A,NRXN3
  16    p11.2-p11.1   LOH              100%                    \-    \-                  SMG1P2
  17    q21.33        Amp              31.43%                  Amp   0.40%               ABCC3
  19    q13.2         Amp              28.57%                  Amp   0.20%               WTIP
  20    q11.3         Del              20.00%                  \-    \-                  PDRG1
  22    q11.23        Amp              45.71%                  \-    \-                  PLA2G6
  X     p22.33        Amp              62.86%                  \-    \-                  XGY2
        q28           Amp              40%                     Amp   0.80%               SPRY3

CNA, copy number alteration; ccRCC, clear cell renal cancer; TCGA, the Cancer Genome Atlas; Chr, chromosome; Del, delete; LOH, loss of heterozygosity; Amp, amplification.

###### 

CN status of the genes in different pathways that are significantly enriched

  Pathways                            Related genes   Chinese            TCGA         
  ----------------------------------- --------------- --------- -------- ------ ----- -------
  Regulation of mRNA stability        EXOSC7          Del       71.43%          Del   10%
                                      PRKCD           Del       71.43%          Del   9%
                                      TRIM71          Del       68.57%          Del   10%
                                      HNRNPA0         Amp       45.71%          Amp   13%
                                      METTL3          Del       11.42%          \-    \-
                                      PSME1           Del       11.42%          \-    \-
  DNA repair                          DDB2            Amp       31.43%          \-    \-
                                      PARP2           Del       11.42%          \-    \-
                                      TTC5            Del       11.42%          \-    \-
                                      APEX1           Del       11.42%          \-    \-
                                      SUPT16H         Del       11.42%          \-    \-
                                      REC8            Del       11.42%          \-    \-
                                      FAN1            Amp       31.43%          \-    \-
                                      EGFR            Amp       37.14%          Del   0.20%
                                      KIF22           LOH       34.29%          Amp   0.20%
                                      PPP4C           LOH       48.57%          Amp   0.20%
                                      INO80E          LOH       42.86%          Amp   0.20%
                                      PAGR1           LOH       34.29%          Amp   0.20%
  DNA modification                    DNMT3A          Amp       11.42%          \-    \-
                                      EHMT2           Amp       11.42%          \-    \-
                                      ASCC1           Del       11.42%          \-    \-
                                      CCNB1IP1        Del       11.42%          \-    \-
                                      CTCF            Del       11.42%          \-    \-
  Notch signaling pathway             MDK             Amp       31.43%          \-    \-
                                      MMP14           Del       11.42%          \-    \-
                                      FOXA1           Del       11.42%          \-    \-
  TOR signaling pathway               TSC2            Del       14.29%          Amp   0.20%
                                      TELO2           LOH       11.43%          Amp   0.20%
                                      WDR24           LOH       11.43%          Amp   0.20%
                                      MLST8           Del       14.29%          Amp   0.20%
  Wnt signaling pathway               PSMB5           Del       11.42%          \-    \-
                                      PSMB11          Del       11.42%          \-    \-
                                      PSME2           Del       11.42%          \-    \-
  Tumor necrosis factor superfamily   PYCARD          LOH       65.71%          Amp   0.20%
                                      GHRL            Del       68.57%          Del   11%
                                      CCR2            Del       74.29%          Del   10%
                                      MYD88           Del       71.43%          Del   10%
                                      LTF             Del       74.29%          Del   11%
  Inflammatory response               TUSC2           Del       68.57%          Del   10%
                                      PPARG           Del       68.57%          Del   11%
                                      IL17RC          Del       71.43%          Del   11%
                                      CCRL2           Del       74.29%          Del   11%
                                      HIF1A           Del       14.29%          Del   0.60%
                                      LTB4R           Del       11.42%          \-    \-
                                      IL25            Del       11.42%          \-    \-
                                      LTB4R2          Del       11.42%          \-    \-
                                      NFATC4          Del       11.42%          \-    \-

CN, copy number; TCGA, the Cancer Genome Atlas; Del, delete; LOH, loss of heterozygosity; Amp, amplification.

###### 

Tumor suppressors and Oncogenes associated with ccRCC in this study

  Function                Genes      Region   Chinese   TCGA              
  ----------------------- ---------- -------- --------- -------- -------- --------
  Tumor suppressors(23)   TADA3      3p25.3   Del       71.43%   Del      11.00%
  VHL\*                   3p25.3     Del      71.43%    Del      11.00%   
  PLCD1                   3p22.2     Del      71.43%    Del      11.00%   
  CSRNP1                  3p22.2     Del      71.43%    Del      11.00%   
  LZTFL1                  3p21.31    Del      74.29%    Del      11.00%   
  LRRC2                   3p21.31    Del      74.29%    Del      11.00%   
  SEMA3B                  3p21.31    Del      66.57%    Del      11.00%   
  NAT6                    3p21.31    Del      68.57%    Del      11.00%   
  TUSC2                   3p21.31    Del      68.57%    Del      11.00%   
  RASSF1                  3p21.31    Del      68.57%    Del      11.00%   
  PCBP4                   3p21.2     Del      71.43%    Del      11.00%   
  BAP1\*                  3p21.1     Del      71.43%    Del      10.00%   
  ERC2-IT1                3p14.3     Del      71.43%    \-       \-       
  PTPRG                   3p14.2     Del      57.14%    Del      5.00%    
  FOXP1                   3p13       Del      42.86%    Del      2.70%    
  RBM5                    3p21.31    Del      68.57%    Del      10%      
  LATS2                   13q12.11   Del      17.14%    Del      0.20%    
  RNF6                    13q12.13   Del      17.14%    Del      0.20%    
  DLK1                    14q32.2    Del      11.43%    Del      0.40%    
  MEG3                    14q32.2    Del      11.43%    Del      0.40%    
  TSC2                    16p13.3    Del      14.29%    Amp      0.20%    
  RNF40                   16p11.2    LOH      57.14%    Amp      0.20%    
  STK11                   19p13.3    Del      20.00%    Del      0.20%    
  Oncogenes (10)          ABL2       1q25.2   Amp       14.29%   Amp      0.80%
  RAB10                   2p23.3     Amp      11.43%    \-       \-       
  ADGRA3                  4p15.2     Amp      11.43%    \-       \-       
  BRAF                    7q34       Amp      17.14%    Amp      0.90%    
  MET\*                   7q31.2     Amp      28.57%    Amp      0.90%    
  LYN                     8q12.1     Amp      14.29%    Amp      0.40%    
  MOS                     8q12.1     Amp      14.29%    Amp      0.40%    
  RAB2A                   8q12.1     Amp      14.29%    Amp      0.40%    
  RNF139                  8q24.13    Amp      14.29%    Amp      0.80%    
  HUWE1                   Xp11.22    Amp      11.43%    Del      0.60%    

\*: The genes associated with renal cancer have been reported in previous studies; -: not available; ccRCC, clear cell renal cancer; TCGA, the Cancer Genome Atlas; Del, delete; LOH, loss of heterozygosity; Amp, amplification.

###### 

CNA burden in ccRCC patients.

  Event                        Average level (%)   No. of cases with high level of CAN (n, %)                
  ---------------------------- ------------------- -------------------------------------------- ------------ ---------
  Amplification                2.91%               13 (46.43%)                                  4 (57.14%)   0.69
  Deletion                     2.49%               13 (46.43%)                                  4 (57.14%)   0.69
  Amplification and deletion   5.40%               13 (46.43%)                                  7 (100%)     0.012\*
  Loss of heterozygosity       5.08%               13 (46.43%)                                  4 (57.14%)   0.69

CNA, copy number alteration; ccRCC, clear cell renal cancer; \*: P-value \< 0.05.
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